TERLIPRESSIN

Other

Brand names: Terlivaz

Intravenous

Mechanism of Action

12.1 Mechanism of Action Terlipressin is a synthetic vasopressin analogue with twice the selectivity for vasopressin V 1 receptors versus V 2 receptors. Terlipressin acts as both a prodrug for lysine-vasopressin, as well as having pharmacologic activity on its own. Terlipressin is thought to increase renal blood flow in patients with hepatorenal syndrome by reducing portal hypertension and blood circulation in portal vessels and increasing effective arterial volume and mean arterial pressure (MAP).

Indications

See full prescribing information

Contraindications

• 4 CONTRAINDICATIONS TERLIVAZ is contraindicated in patients experiencing hypoxia or worsening respiratory symptoms. TERLIVAZ is contraindicated in patients with ongoing coronary
• peripheral or mesenteric ischemia. TERLIVAZ is contraindicated: In patients experiencing hypoxia or worsening respiratory symptoms. ( 4 ) In patients with ongoing coronary
• peripheral
• or mesenteric ischemia. ( 4 )

FDA Warnings

5 WARNINGS AND PRECAUTIONS Serious or Fatal Respiratory Failure : Monitor patients for changes in respiratory status using pulse oximetry and regular clinical assessments
1 Serious or Fatal Respiratory Failure In the primary clinical trial [see Clinical Studies (14) ] , serious or fatal respiratory failure occurred in 14% of patients treated with TERLIVAZ compared to 5% of patients on placebo
Patients with fluid overload may be at increased risk of respiratory failure
Avoid use in patients with ACLF Grade 3 because they are at significant risk for respiratory failure [see References (15) ]

Known Side Effects

2 documented side effects by frequency

Drug Not Working

>10%

Diarrhea

1-10%

Community Discussions

No community discussions found for TERLIPRESSIN yet.

Compare With

0 available comparisons

No comparisons yet.

Formulations

Dosage Forms

Tablet

Route

Intravenous